Urine-derived stem cell therapy - EHL Bio
Alternative Names: KDSTEM Injection; UDSC - EHL BioLatest Information Update: 28 Mar 2024
At a glance
- Originator EHL Bio
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Renal failure
Most Recent Events
- 29 Feb 2024 Phase-I clinical trials in Renal failure (In adults, In the elderly) in South Korea (IV) (NCT06071143)
- 25 Oct 2023 Preclinical trials in Renal failure in South Korea (IV), prior to October 2023 (EHL Bio pipeline, October 2023)
- 19 Oct 2023 EHL Bio plans a phase I trial for Renal failure in South Korea (IV, Injection), in November 2023 (NCT06071143)